Streetbeat News

CMND

Clearmind Medicine Inc.

https://www.clearmindmedicine.com

Industry

Biotechnology

Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, including binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.

Open

1.40

Mkt cap

5.7M

Volume

41K

High

1.40

P/E Ratio

-1.14

52-wk high

6.80

Low

1.36

Div yield

N/A

52-wk low

0.92

Clearmind Medicine Inc. (NASDAQ:CMND) has announced advancements in its proprietary MEAI-based alcohol substitute beverage program. The company is moving forward with the last pre-clinical study required for a novel-food application submission.

Portfolio Pulse from Benzinga Newsdesk

June 11, 2024 | 12:00 pm

Clearmind Medicine has made progress in its program to develop a MEAI-based alcohol substitute beverage, targeting the growing no- and low-alcohol beverage market valued at over $13 billion in 2023.

Portfolio Pulse from Benzinga Newsdesk

May 10, 2024 | 12:26 pm

Beyond, Inc. (NYSE:BYON) shares plummeted over 20% due to disappointing quarterly results, missing both earnings and revenue estimates. Other stocks experienced significant movements, with companies like Golden Sun Health Technology Group Limited (NASDAQ:GSUN) and MMTec, Inc. (NASDAQ:MTC) seeing substantial gains. The article also highlights losers of the day, including Holdco Nuvo Group D.G Ltd (NASDAQ:NUVO) and The Real Good Food Company, Inc. (NASDAQ:RGF), which saw notable declines.

Portfolio Pulse from Avi Kapoor

May 07, 2024 | 6:35 pm

Clearmind Medicine Inc. (NASDAQ:CMND) shares surged after announcing an exclusive patent licensing agreement with Yissum Research Development to develop and commercialize compounds for treating PTSD and other mental health conditions. This agreement is seen as a significant step in addressing mental health care needs with innovative psychedelic compounds. The global market for PTSD treatment, valued at $16.8 billion in 2023, is expected to grow to $27.37 billion by 2033.

Portfolio Pulse from Dylan Berman

May 07, 2024 | 3:03 pm

Clearmind Medicine (CMND) shares surged 60% following an exclusive patent licensing agreement with Yissum Research Development Company. Hims & Hers Health (HIMS) shares rose 18% after reporting Q1 financial results that exceeded expectations and providing optimistic Q2 and FY24 revenue guidance. Dave (DAVE) shares increased 22% after announcing better-than-expected Q1 financial results and FY24 operating revenue forecast.

Portfolio Pulse from ryanfaloona@benzinga.com

May 07, 2024 | 12:36 pm

Clearmind Medicine's stock is trading higher following the announcement of an exclusive patent licensing agreement with Yissum Research Development Company.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 11:49 am

Clearmind (CMND) has secured exclusive global rights to develop, manufacture, and commercialize innovative compounds invented by Professors Rami Yaka, Ahmed Masaewa, and Avi Priel from The Hebrew University.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 11:48 am

Clearmind Medicine has entered into an exclusive patent licensing agreement with Yissum Research Development Company. This agreement grants Clearmind exclusive rights to develop, manufacture, and commercialize novel compounds aimed at treating PTSD and other mental health disorders.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 11:47 am

Clearmind Medicine Inc. (CMND) announced its intention to cease being a reporting issuer in Canada, which would end its obligation to file financial statements and other continuous disclosure documents with Canadian Securities Regulators. Despite this, Clearmind will continue to meet disclosure requirements in the United States and Germany, adhering to the laws and rules of the Nasdaq and the Frankfurt Stock Exchange. All disclosure documents will remain accessible to security holders, including those in Canada, through the company's website.

Portfolio Pulse from Benzinga Newsdesk

April 30, 2024 | 9:18 pm

The article provides a comprehensive roundup of recent developments in the psychedelics field, including research findings, global regulatory perspectives, therapeutic applications, and business news. Key highlights include potential roles of psilocybin in dementia prevention and psychological flexibility, global legalization trends, and various companies' strategic moves such as voluntary delistings, partnership agreements, financial results, and patent filings related to psychedelic therapies.

Portfolio Pulse from Lara Goldstein

April 17, 2024 | 1:13 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.